Clinical Trial: CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Brief Summary: The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.

Detailed Summary:
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Current Primary Outcome: Phase I: Adverse events attributed to the administration of the anti-CD19 CAR-T cells [ Time Frame: 2 years ]

Original Primary Outcome: Same as current

Current Secondary Outcome: Phase II: Objective Response Rate [ Time Frame: Safety follow-up is 100 days from last CAR-T infusion. ]

Original Secondary Outcome: Same as current

Information By: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Dates:
Date Received: June 28, 2016
Date Started: October 2016
Date Completion: September 2019
Last Updated: October 23, 2016
Last Verified: October 2016